Cholera vaccination campaigns are restarting after a three-year-long pause due to limited supplies. The first vaccine shipments arrived in Mozambique and the Democratic Republic of Congo at the end of 2025, and delivery plans are underway for Bangladesh.
The resumption of prevention campaigns against cholera — a diarrheal disease that can be fatal if not treated within hours — have been made possible by multipronged efforts over the years to beef up the oral cholera vaccine, or OCV, supply stockpile, which for the longest time had been reliant on two manufacturers: Indian manufacturer Shantha Biotechnics and the South Korean company EuBiologics, which produces Euvichol.
Shantha ceased production of its vaccine in 2022, leaving EuBiologics as the sole manufacturer of the OCV for both outbreak response and prevention campaigns — at a time of widespread global outbreaks.
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
